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ABSTRACT
To overcome cancer cells resistance to pharmacological therapy, the development 
of new therapeutic approaches becomes urgent. For this purpose, the use of poly(ADP-
ribose) polymerase (PARP) inhibitors in combination with other cytotoxic agents could 
represent an efficacious strategy. Poly(ADP-ribosyl)ation (PARylation) is a post-
translational modification that plays a well characterized role in the cellular decisions 
of life and death. Recent findings indicate that PARP-1 may control the expression 
of Snail, the master gene of epithelial-mesenchymal transition (EMT). Snail is highly 
represented in different resistant tumors, functioning as a factor regulating anti-
apoptotic programmes. MDA-MB-231 is a Snail-expressing metastatic breast cancer cell 
line, which exhibits chemoresistance properties when treated with damaging agents. In 
this study, we show that the PARP inhibitor ABT-888 was capable to modulate the MDA-
MB-231 cell response to doxorubicin, leading to an increase in the rate of apoptosis. 
Our further results indicate that PARP-1 controlled Snail expression at transcriptional 
level in cells exposed to doxorubicin. Given the increasing interest in the employment 
of PARP inhibitors as chemotherapeutic adjuvants, our in vitro results suggest that one 
of the mechanisms through which PARP inhibition can chemosensitize cancer cells in 
vivo, is targeting Snail expression thus promoting apoptosis.
INTRODUCTION
Breast cancer is the most common malignant tumor 
in women. Despite advances in diagnosis and treatment 
approaches, the mortality due to breast cancer still remains 
very high. This is attributable to the fact that cancer cells are 
able to develop mechanisms of resistance to the therapeutic 
treatment, a process known as chemoresistance [1, 2]. In 
particular, the treatment of some kind of triple negative 
breast cancer (TNBC) -so called because the cancer cells 
lack receptor for estrogen (ER-) and progesterone (PR-) and 
do not express the human epidermal growth factor receptor 
2 (HER2-)- is quite complex because to an initial response 
follows a resistance to therapy [3].
Epithelial-mesenchymal transition (EMT) is a 
transdifferentiation program that is required for tissue 
morphogenesis during embryonic development and 
abnormally activated during tumor progression [4–6]. 
Through EMT, epithelial cells lose their cell-cell adhesion 
molecules, their polarity, rearrange their cytoskeleton 
and become prone to migrate [7]. Recent evidence now 
indicates that EMT of tumor cells not only promotes the 
development of metastases,  but also contributes to drug 
resistance [8–12]. Ultimately, Snail, the fundamental 
member of the family of Snail transcriptional factors 
[13], has emerged as factor able to increase the resistance 
of cancer cells [14, 15]. It has been demonstrated that 
aberrant expression of Snail promotes resistance to 
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programmed cell death in MCF-7 cells elicited by 
doxorubicin [14]. Moreover, Snail has been reported to be 
sufficient to promote mammary tumor recurrence in vivo 
and high levels of Snail predict decreased relapse-free 
survival in women with breast cancer [16]. Other studies 
have shown that Snail confers resistance to cell death 
induced by lack of survival factors and by pro-apoptotic 
signals [17] and that Snail downregulation increases cell 
death in colon tumors in a mouse model [18]. Snail exerts 
its function not only through the repression of epithelial 
genes such as CDH1 (E-cadherin) [19] but also through 
repression of multiple factors with important functions in 
apoptosis such as TP53, BID, and Caspase-6 [14, 20] or 
PTEN, a negative effector of the PI3K pathway [21].
Snail expression is regulated at transcriptional level 
by growth factors and various signaling molecules [22] 
as well as by Snail protein itself [23]. In addition, some 
post-translational modifications influence Snail stability, 
subcellular localization and activity [24–26]. Moreover, it 
has been shown that the expression of Snail can be directly 
activated by the enzyme PARP-1 at transcriptional level 
[27] and that the modification of Snail by PARP activity 
stabilizes Snail protein at post-translational level [24].
Recent findings have revealed that PARP-1 plays 
a role in EMT and metastasis formation by affecting the 
expression of epithelial and mesenchymal genes [28–31]. 
To investigate the relationship between PARP-1 and Snail, 
we have to keep in mind the pleiotropic actions of PARP-1. 
PARP-1 is an abundant and ubiquitous nuclear enzyme [32, 
33], which is implicated in multiple pathways involved in 
the regulation of gene expression [34–39]. In response to 
stresses that are toxic to the genome, PARP-1 binds single 
or double-stranded DNA breaks and its activity increases 
with the aim to maintain genomic integrity [40, 41]. 
Massive PARP-1 activation, however, consumes NAD+ 
and ATP, leading to energy failure and cell death [42, 43]. 
A delicate PARP-1 activity equilibrium exists within cells 
where any deviation, either hyper- or hypo-activity can 
change the cell decision of life or death [44]. PARP-1 is 
an attractive anticancer target [45, 46] and PARP inhibitors 
used as monotherapy, induce cell death in tumors with 
non-functional homologous recombination because of 
defective BRCA pathways [47–49]. PARP inhibitors are 
also used in combination with chemotherapeutic agents 
to strengthen the effect of DNA damage in sporadic 
tumors [50–52]. As previously described [53–55], PARP 
inhibitors, when used in combination with doxorubicin 
(doxo), are able to chemosensitize p53-mutated, TNBC 
MDA-MB-231 cells. In this paper, we aim to explore 
whether this chemosensitizing effect may depend on 
the regulation of Snail transcription by PARP-1. As 
expected, the combined doxo-ABT-888 treatment led to 
an increase in the rate of apoptosis. We show that Snail 
levels, which were upregulated by doxo treatment, were 
decreased by ABT-888 addition or by depletion of PARP-
1. The involvement of PARP-1 in Snail transcription was 
further demonstrated by chromatin immunoprecipitation 
(ChIP) and luciferase assays. The milder upregulation 
observed upon combined doxo/ABT-888 treatment or 
PARP-1 depletion appeared to be crucial for releasing 
PTEN suppression, a key negative regulator of PI3K/
Akt activity. The lower activation of PI3K/Akt pathway 
resulted in the reduction of the survival signaling. Our data 
reveal potential implications in the use of PARP inhibitors 
in combination with doxo in therapeutic intervention of 
some chemoresistant Snail-expressing tumors.
RESULTS
ABT-888 treatment and PARP-1 depletion 
sensitize MDA-MB-231 cells to doxo-induced 
apoptosis
Doxo has multiple effects on tumor cells, including 
DNA damage, and prolonged exposure to this agent causes 
the activation of the apoptotic program in most of cancer 
cell lines [56]. However, some cells are able to escape 
apoptosis and develop resistance to drug treatment [57]. We 
aimed to evaluate the apoptotic response of MDA-MB-231 
cells and its dependence on PARP inhibition. Since we 
obtained similar results using different PARP inhibitors, 
here we decided to use ABT-888, a novel PARP inhibitor 
that has been reported to make the tumor more likely to 
respond to radiation and chemotherapy [58]. MDA-MB-231 
cells were treated with either 1 μM doxo, or 0.5 μM ABT-
888, or a combination of both drugs for 24–48 h.
The presence of apoptotic cells was examined by 
FACS analysis, counting all the Annexin V positive cells 
in the right squares of each panel in Figure 1A. A moderate 
increase in the number of apoptotic cells was evident in 
doxo-treated vs untreated cells at 24 and 48 h. Conversely, 
the number of Annexin V positive cells significantly 
increased at 24 and 48 h of combined treatment with doxo 
and ABT-888 (up to 2.6-fold vs untreated cells) (Figure 1B). 
Accordingly, when the effect of doxo and ABT-888, alone 
or in combination, was evaluated in terms of clonogenic 
ability, the combined treatment resulted in a significant 
reduction in clonogenic ability of MDA-MB-231 cells (9% 
survival fraction) with respect to doxo alone (27% survival 
fraction) or ABT-888 alone (85% survival fraction) (data 
not shown).
Consistently, only cells exposed to doxo and ABT-
888 for 24 h exhibited an increased level of cleaved PARP-
1 (detected with clone mAb C2–10), a widely sensitive 
indicator of caspase-mediated apoptotic cell death, and 
a concomitant increase in γH2AX formation, which is 
indicative of an unrepaired damage (Figure 1C).
Then we assessed whether also the depletion of 
PARP-1 caused the same outcome of the PARP inhibitor 
ABT-888 in terms of apoptosis. After siRNA-mediated 
silencing of PARP-1, MDA-MB-231 cells were treated with 
doxo for 24 and 48 h and apoptosis was evaluated by the 
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Annexin V assay. Graph in Figure 1D shows a significant 
increase of apoptosis (about 3 fold) in cells silenced for 
PARP-1 with respect to control cells after doxo treatment. 
Concomitant with this effect, a higher induction of γH2AX 
was detectable after 24 h of doxo treatment in siPARP-1 
cells with respect to control cells (Figure 1E).
Collectively, these data indicate that reduction of PARP 
activity may enhance the killing effect of doxo on tumor cells 
and that this effect may primarily depend on PARP-1.
PARP-1 activity is required for Snail 
upregulation in different doxo-treated breast 
cancer cell lines
Although the mechanisms of apoptosis are complex, 
there is accumulating evidence to suggest that Snail 
is an important component in defining the response of 
tumor cells to chemotherapeutic agents [15]. Since the 
PARylation process has been correlated to the modulation 
FIGURE 1: ABT-888 treatment and PARP-1 depletion sensitize MDA-MB-231 cells to doxo-induced apoptosis.  
A. Apoptosis was analysed by FACS after treatment of MDA-MB-231 cells with 1 μM doxo and/or 0.5 μM ABT-888 for 24 and 48 h. Panels 
of a representative experiment are shown. B. Annexin V positive cells were counted in the right upper and lower squares. The diagram reports 
the percentage of Annexin V positive cells in untreated cells (black bar) and after treatment with 1 μM doxo (white bars), 1 μM doxo plus 
0.5 μM ABT-888 (light gray bars) or ABT-888 alone (dark gray bars) at the indicated times in relation to total cells. Data represented are 
the mean+SEM of at least three independent experiments performed in duplicates. Comparisons were made with ANOVA/Turkey’s test. 
*P < 0.05 compared to untreated cells; #P < 0.05 compared to cells treated with doxo at 24 h, 48 h respectively. C. Levels of cleaved PARP-1 
(detected with mAb clone C2-10, Enzo Life Sciences) and γH2AX protein were measured by Western blot analyses in MDA-MB-231 cells 
treated for 24 h with 1 μM doxo and/or 0.5 μM ABT-888. D. Annexin V positive cells were counted in the right upper and lower squares. 
The diagram reports the percentage of Annexin V positive cells in siCT cells untreated (black bar) or treated with doxo (white bars) and in 
siPARP-1 cells untreated (black bar) or treated with doxo (light gray bars). Comparisons were made with ANOVA/Turkey’s test. *P < 0.05 
compared to untreated cell; #P < 0.05 compared to cells treated with doxo at 24 h, 48 h respectively. E. Levels of PARP-1 and γH2AX protein 
were measured by Western blot analyses in siCT MDA-MB-231 cells and in siPARP-1 MDA-MB-231cells treated for 24 h with 1 μM doxo.
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of Snail level [24, 27], we aimed to evaluate its role in 
Snail expression during doxo treatment in MDA-MB-231. 
Cells were treated with either doxo 1 μM, or ABT-888 
0.5 μM or a combination of both drugs at different times 
(2 h, 7 h and 24 h). As shown by Western blot analyses 
(Figure 2A), Snail levels increased in a time-dependent 
manner upon treatment with doxo, while the combined 
treatment with both doxo and ABT-888 resulted in a 
milder induction. This decrease in Snail level is significant, 
as revealed by densitometric analyses in Figure 2B. 
PAR level is quite high in our untreated cells probably 
because of the higher rate of basal PARP-1 activity, often 
observed in cancer cells [59]. However, the efficacy of 
PARP inhibition was confirmed by PAR disappearance in 
presence of ABT-888 alone or in combination with doxo. 
Real-Time PCR analyses were performed to determine 
whether the variation of Snail protein was correlated to 
changes of its mRNA expression. Figure 2C shows that 
SNAI1 mRNA levels significantly upregulated in a time-
dependent manner after doxo treatment, reaching very 
high levels at 24 h (114 fold increase vs untreated cells) 
while cotreated cells showed a decrease in SNAI1 mRNA 
levels (30 + 7% at 24 h). The SNAI1 mRNA levels of 
ABT-888 treated cells did not show a significant difference 
compared to untreated cells.
To assess whether PARP-1 was involved in the 
modulation of Snail induction after doxo treatment, 
MDA-MB-231 cells were silenced for PARP-1 by 48 h 
of siRNA transfection and then treated with doxo for 7 h. 
Western blot analyses (Figure 2D) indicate a considerable 
reduction of Snail level after doxo treatment in PARP-1-
depleted cells with respect to control cells. Densitometric 
analysis shows that Snail decrease is significant (Figure 
2E). Again, Real-Time PCR analysis indicates that the 
sharp increase of SNAI1 mRNA level upon doxo treatment 
in siCT cells was significantly reduced in PARP-1-silenced 
cells (Figure 2F).
Then we compared the effects of doxo and ABT-
888 treatments on Snail expression in the two additional 
TNBC cell lines MDA-MB-468 and MDA-MB-157, and 
in the epithelial cell line MCF-7. Regarding the triple 
negative cells, while MDA-MB-468 cells exhibited a 
time-dependent consistent increase in Snail protein and 
mRNA level in response to doxo (Supplementary Figure 
1A and 1B), MDA-MB-157 cells exhibited a significant (5 
fold) increase only at 24 h of doxo treatment with respect 
to untreated cells (data not shown). Notably, both triple-
negative cancer cells showed a significant reduction of 
the doxo-induced Snail level in cells cotreated with ABT-
888 and doxo, suggesting a positive effect of the PARP 
inhibitor as antitumor agent in this subset of breast tumors. 
In spite of the low basal Snail level, also MCF-7 cell line 
evidenced an increase in Snail protein and mRNA level 
upon doxo treatment, (less consistent at mRNA level than 
in MDA-MB-231 cells), which was counteracted by ABT-
888 cotreatment (Supplementary Figure 1C, 1D).
Collectively, these results indicate that PARP-1 
regulates Snail expression following doxo treatment.
PARP activity affects PARP-1 binding and 
histone H3 modifications profiles at SNAI1 locus 
in doxo-exposed MDA-MB-231 cells
Snail promoter contains an E-box motif, defined 
as the binding site of PARP-1 located within the Snail-
ILK responsive element (SIRE) sequence [27, 60]. To 
investigate whether Snail promoter activity directly 
responds to PARP-1, the transfection with a luciferase 
reporter construct [61] carrying the human Snail promoter 
was combined with the silencing of PARP-1 in MDA-
MB-231 cells (Figure 3A). The depletion of PARP-1 
expression at 48 h from siRNA transfection was controlled 
by Western blot (data not shown). Snail promoter activity 
was measured after exposure of transfected cells to doxo for 
7 h. We noticed that doxo treatment resulted in an increase 
in Snail promoter activity in control samples, which was not 
observed in PARP-1 depleted samples. This result shows 
that PARP-1 depletion negatively regulated Snail promoter 
activation induced by doxo and this is in agreement with the 
expression of endogenous Snail, which was downregulated 
at protein and mRNA level (Figure 2D, 2F).
To obtain information about the direct role played 
by PARP-1 in SNAI1 expression in MDA-MB-231 
cells, ChIP assays were performed to analyse PARP-
1 interactions with the promoter and the 3′ enhancer 
(Figure 3B), a region that is reported to control the 
expression of Snail in melanoma cells A375 [62]. 
Analyses were performed in MDA-MB-231 cells treated 
for 7 h with either doxo 1 μM, or ABT-888 0.5 μM or 
a combination of both drugs. As shown in Figure 3C, 
PARP-1 occupied the promoter and enhancer regions 
both in presence and in absence of ABT-888. This 
binding was abrogated upon doxo treatment. Doxo/ABT-
888 cotreatment counteracted PARP-1 removal from 
the SNAI1 promoter/enhancer regions. To confirm the 
specificity of our ChIP assays, we carried out a positive 
control consisting in the amplification of a region 
on ITPR1 promoter, positively regulated by PARP-1 
(Supplementary Figure 2) [63]. Thus, PARP-1 is not 
present on the promoter/enhancer regions when Snail is 
upregulated upon doxo treatment while it reappears on 
those regions when Snail induction is lowered by the 
doxo/ABT-888 cotreatment.
ChIP assays were performed in order to characterize 
the histone modification profile at the SNAI1 promoter and 
its response to treatments. Figure 3D shows that H3K27 
trimethylation (H3K27me3), found in facultatively 
repressed genes, was not present in any of the analyzed 
conditions. Conversely, acetylated H3 (H3Ac) and H3K4 
trimethylation (H3K4me3), which are associated to 
actively transcribed promoters, occupied the promoter 
indicating its “on” state. H3K4me3 increased significantly 
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as the gene was induced by doxo treatment with respect to 
untreated, cotreated or ABT-888-treated cells.
Collectively, these results reveal an important role 
of PARP activity in defining the right chromatin context of 
SNAI1 promoter in response to doxo and suggest a direct 
involvement of PARP-1.
PARP-1 inhibition/depletion antagonizes doxo-
induced downregulation of PTEN in MDA-
MB-231 cells and decreases Akt activity
Snail represses pro-apoptotic genes in the DNA 
damage response pathway, promoting cell survival [14, 
20]. Previous results showed that, upon DNA damage, 
Snail physically associates with the PTEN promoter and 
inhibits its expression [21]. We asked whether the doxo-
induced upregulation of Snail was able to repress PTEN 
expression in MDA-MB-231 cells and whether ABT-888 
treatment or PARP-1 depletion, by antagonizing Snail 
upregulation, could play a role in modulating PTEN 
expression. Real-Time PCR analysis (Figure 4A) showed 
a drastic decrease in PTEN expression in cells exposed to 
doxo that was significantly counteracted by cotreatment 
with ABT-888. The PTEN mRNA levels following doxo 
and doxo/ABT-888 treatment resulted inversely correlated 
to the Snail level which is in agreement with the reported 
function of Snail on PTEN repression.
PTEN is a phosphatase, which provokes Akt 
dephosporylation and its inhibition [64]. Therefore 
PTEN suppression should cause Akt activation. Western 
FIGURE 2: PARP-1 activity is required for Snail upregulation in doxo-treated MDA-MB-231 cells. MDA-MB-231 cells 
were treated with 1 μM doxo, 1 μM doxo plus 0.5 μM ABT-888, 0.5 μM ABT-888 alone at the indicated times. A. PAR, PARP-1 (detected 
with mAb clone F1–23 Enzo Life Sciences) and Snail levels were assessed by Western blot analysis B. Graph shows the average densitometry 
of Snail values normalized to actin, considering Snail level in untreated cells as 1.0. Data represent mean + SEM of three independent 
experiments. *P < 0.05, **P < 0.01 by Student’s t-test. C. Expression levels of SNAI1 mRNA were assessed by Real-Time PCR after 2 h 
(white bars), 7 h (light gray bars) and 24 h (dark gray bars) of treatment and compared to untreated cells (black bar) considered as 1.0. Data 
represent mean + SEM of at least five independent experiments performed in triplicates. *P < 0.05, **P < 0.01 by Students t-test. D. Snail 
protein level was assessed by Western blot in MDA-MB-231 cells silenced for PARP-1 after treatment with 1 μM doxo for 7 h. E. Graph 
shows the average densitometry of Snail values normalized to actin, considering Snail level in untreated cells as 1.0. Data represent mean + 
SEM of three independent experiments. *P < 0.05 by Student’s t-test. F. Levels of SNAI1mRNA in MDA-MB-231 cells silenced for PARP-1 
(dark gray bars) after treatment with 1 μM doxo for 7 h in relation with cells transfected with siCT (light gray bars). Data represent mean + 
SEM of three independent experiments performed in triplicates. **P < 0.01 by Student’s t-test.
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FIGURE 3: PARP activity affects PARP-1 binding and histone H3 modifications profiles at SNAI1 locus in 
doxo-exposed MDA-MB-231 cells. A. Dual-luciferase assay of MDA-MB-231 cells transfected with a Snail reporter plasmid 
and siRNA to knockdown PARP-1. Results are presented as variation of light units measured in siCT cells (light gray bars) exposed 
to doxo and in untreated and doxo-exposed siPARP-1 cells (black bars) relatively to the activity of siCT untreated cells, set as 1.0. 
Data (mean and SEM) are representative of at least three independent experiments. *P < 0.05 by Student’s t-test. B. Schematic 
view of the human SNAI1 gene, comprised of three exons. Among the regulatory elements, a CpG island in the promoter region and 
an enhancer, corresponding to a DNase hypersensitive site, are highly conserved. The position of the primers pair used to amplify 
the indicated sequence of the promoter region (length 117bp) and enhancer region (length 110bp) are reported. C. MDA-MB-231 
cells, treated for 7 hours with 1 μM doxo, 0.5 μM ABT-888, 1 μM doxo plus 0.5 μM ABT-888, were fixed and lysed. ChIP assays 
for PARP-1 were conducted and DNA isolated from PARP-1 IPs was used in Real-Time PCR to amplify the indicated genomic 
loci on promoter (left panel) and on enhancer (right panel). DNA coprecipitated with control IgG was also amplified to control 
aspecific signal. D. MDA-MB-231 cells, treated for 7 hours with 1 μM doxo, 0.5 μM ABT-888, 1 μM doxo plus 0.5 μM ABT-888, 
were fixed and lysed ChIP assays for H3Ac, H3K4me3 and H3K27me3 were conducted. DNA was isolated from IPs and used 
in Real-Time PCR to amplify the indicated genomic locus on SNAI1 promoter. DNA coprecipitated with control IgG was also 
amplified to control aspecific signal. Each experiment of Real-Time PCR was conducted in triplicates and depicted as the average 
of immunoprecipitated signal to input signal and SEM. Data represent averages of three experiments.*P < 0.05, **P < 0.01, ***P 
< 0.001 by Students t-test.
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blot analysis evidenced (Figure 4B) that the treatment of 
MDA-MB-231 cells with doxo increased Akt(Ser473) 
phosphorylation, in accordance with the reduction of PTEN 
which was confirmed at protein level too. Conversely, 
the cotreatment with doxo/ABT-888, which allowed the 
recovery of PTEN at mRNA and protein level, induced a 
decrease in Akt activation thus favouring apoptosis.
In line with the result of the combined treatment, 
we showed that the depletion of PARP-1 caused a 
lower suppressive effect on PTEN expression with 
respect to control cells upon doxo treatment (Figure 
4C). Consistently, Western blot analysis shows that 
the increased Akt(Ser473) phosphorylation detected in 
control cells upon doxo treatment was reduced in PARP-
1-depleted cells (Figure 4D).
Snail knockdown sensitizes MDA-MB-231 cells 
to doxo-induced apoptosis and allows recovery of 
PTEN expression
To confirm that the rate of apoptosis in MDA-MB-231 
cells depended on Snail levels, MDA-MB-231 cells were 
transfected with shRNA-Snail or shRNA-CT plasmids. 
Figure 5A shows that depletion of endogenous Snail was 
efficient as Snail signal resulted low after doxo treatment 
too. A significant increase in the number of Annexin V 
FIGURE 4: PARP-1 inhibition/depletion antagonizes doxo-induced downregulation of PTEN in MDA-MB-231 cells 
and decreases Akt activity. A. Expression levels of PTEN after treatment with 1 μM doxo, 1 μM doxo plus 0.5 μM ABT-888 or ABT-
888 for 7 h (light gray bars) or 24 h (dark gray bars) in relation to untreated cells (white bar), considered as 1.0. Data represent mean+SEM 
of at least five independent experiments performed in triplicates. *P < 0.05, **P < 0.01 by Student’s t-test. B. Levels of Akt, phospho-Akt, 
PTEN and γH2AX protein were measured by Western blot analyses in MDA-MB-231 cells treated for 24 h with 1 μM doxo and/or 0.5 μM 
ABT-888 as indicated. C. Expression levels of PTEN after treatment of siCT and siPARP-1 MDA-MB-231 cells with 1 μM doxo for 7 h 
(light gray bars) or 24 h (dark gray bars) in relation to untreated siCT and siPARP-1 cells (white bars), considered as 1.0. Data represent 
mean+SEM of three independent experiments performed in triplicates. *P < 0.05 by Student’s t-test. D. Levels of PARP-1, Akt, phospho-
Akt, and PTEN protein were measured by Western blot analyses in siCT and siPARP-1 MDA-MB-231 cells treated for 24 h with 1 μM doxo.
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positive cells after treatment with doxo at 24–48 h was 
observed in Snail-depleted cells with respect to control cells 
(around 3 fold) (Figure 5B). These data demonstrate that 
Snail deficiency is required for efficient apoptosis in doxo-
treated cells and support the idea that PARP-1 inhibition/
depletion sensitizes MDA-MB-231 cells by limiting Snail 
upregulation. Interestingly, Real-Time PCR analysis 
(Figure 5C) showed that, upon doxo treatment, the clear 
PTEN downregulation of control cells was not detectable 
in Snail-depleted cells. This result is in agreement with the 
presence of high Snail levels and their repressive function on 
PTEN expression in control cells exposed to doxo.
DISCUSSION
Recent studies have evidenced that PARP inhibitors 
may chemosensitize TNBC cell lines [53–55]. Also known 
is that Snail can regulate cancer cell survival [14, 15] and 
that PARP-1 may be involved in its regulation [24, 27].
FIGURE 5: Snail knockdown sensitizes MDA-MB-231 cells to doxo-induced apoptosis and allows recovery of PTEN 
expression. A. Levels of Snail protein were measured by Western blot analyses in shCT and shSnail MDA-MB-231 cells treated for 
24 h with 1 μM doxo B. Annexin V positive cells were counted in the right upper and lower squares. The diagram reports the percentage 
of Annexin V positive cells in untreated shCT and shSnail cells (black bars) and after treatment of shCT (white bars) and shSnail cells 
(light gray bars) with 1 μM doxo at the indicated times in relation to total cells. Data represented are the mean+SEM of three independent 
experiments performed in duplicates. Comparisons were made with ANOVA/Turkey’s test. *P < 0.05, **P < 0.01 compared to cells treated 
with doxo at 24 h, 48 h respectively. C. Expression levels of PTEN after treatment of shCT and shSnail MDA-MB-231 cells with 1 μM 
doxo for 7 h (light gray bars) or 24 h (dark gray bars) in relation to untreated shCT and shSnail cells (white bars), considered as 1.0. Data 
represent mean+SEM of three independent experiments performed in triplicates. *P < 0.05 by Student’s t-test.
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Here we aim to investigate the possible cross-talk 
between PARP-1 and Snail in MDA-MB-231 cells, a 
model of Snail-expressing TNBC cell line, in response to 
the chemotherapeutic agent doxorubicin.
First, we showed that the PARP inhibitor ABT-888 
or PARP-1 depletion increases the sensitivity to doxo. 
Consistently, the combined doxo/ABT-888 treatment 
caused a concomitant increase in γH2AX formation 
associated to a significant reduction in clonogenic ability. 
Then we investigated whether this chemosensitizing effect 
was linked to the control of Snail expression exerted by 
PARP-1. Our results demonstrate that both ABT-888 
treatment and PARP-1 depletion were able to counteract 
the strong upregulation of Snail observed upon treatment 
with doxo. Thus, PARP-1 seems to play a positive role 
in the regulation of Snail expression, thereby favoring 
the survival of cancer cells. One attractive hypothesis is 
that activation of PARP-1 may grant the low cytotoxicity 
of MDA-MB-231 cells by promoting not only the DNA 
repair process but also Snail induction. Conversely, the 
decrease of PARP-1 activity may allow efficient apoptosis 
by blocking DNA repair and reducing Snail level. 
Interestingly, Snail is still upregulated upon combined 
treatment, indicating that Snail expression did not depend 
only on PARP-1. Other pathways may control Snail level 
in DNA damage response [65, 66] or route it in different 
processes from cell survival such as the EMT [26].
Results on the different cell lines led to the 
important conclusion that PARP activity always provides 
a contribution in Snail expression, albeit variable in 
dependence of the cell line [59]. In fact, we observed a 
trend of Snail level to rise after doxo and to fall after doxo/
ABT-888 treatment both in the TNBC cell lines and in 
MCF-7 cells. Our preliminary results (data not shown) and 
recent literature [67, 68] indicate that Snail functions are 
not necessarily related to cell survival in p53-proficient 
MCF-7 cells. In fact, in MCF-7 cells Snail is implicated 
in regulating various targets of the EMT process unlike 
the p53-mutated TNBC cell lines where Snail acts as 
an anti- apoptotic factor [15, 17]. Thus in MCF-7 cells, 
PARP-1 might participate to the EMT process through 
Snail modulation.
Further, the silencing of PARP-1 in MDA-MB-231 
cells has demonstrated that PARP-1 was crucial for the 
induction of the SNAI1 promoter transcriptional activity. 
More information was obtained by ChIP assays, which 
investigated the binding of PARP-1 to specific regions 
at the SNAI1 locus. In untreated or ABT-888-treated 
cells, PARP-1 occupied the SNAI1 promoter/enhancer 
regions and its presence was correlated to Snail basal 
transcription. This suggests that PARP-1, independently 
of its activity [69], may act as gene-specific coregulator 
providing features of permissive/active chromatin. On the 
contrary, PARP-1 no longer occupied the SNAI1 promoter 
and enhancer regions upon doxo treatment, indicating 
that PARP-1 activation and its displacement from DNA 
are important events in the induction mechanism of Snail 
expression. Consistently, PARP inhibition reestablished 
PARP-1 occupancy of the DNA loci after combined 
doxo/ABT-888 treatment, giving rise to a lower Snail 
upregulation.
ChIP analyses for chromatin marks showed that 
H3K27me3 was not present on SNAI1 promoter in 
any of the analyzed conditions while active histone 
modifications (H3Ac and H3K4me3) were well 
represented, indicating the “on” state of the promoter. 
We speculate that PARP-1 allows the recruitment 
of positive modifiers such as histone acetylases and 
histone methyltransferases in absence of any damaging 
stimulus. The importance of the basal activity of PARP-
1 in H3 acetylation is supported by H3Ac depletion 
arisen from exposure to ABT-888 either in presence 
or absence of doxo. As the gene was induced by doxo 
treatment, H3K4me3 increased significantly, suggesting 
the possibility that newly synthesized PARs on PARP-1 
may block the access of some negative effector to the 
promoter, such as the lysine demethylase 5B (KDM5B) 
which is therefore kept far from the promoter [63].
Further experiments were carried out to individuate 
pro-apoptotic targets of Snail affected by PARP inhibition/
depletion. We focused our attention on different targets 
from p53, since in MDA-MB-231 cells, p53 results to be 
highly expressed and its function impaired. According to 
recent papers [21, 70], Snail can activate Akt by repressing 
the PI3K negative regulator PTEN, a direct Snail target. 
Our Real-Time PCR results show that in cells exposed to 
doxo the strong PTEN downregulation was counteracted 
by cotreatment with ABT-888 or by depletion of PARP-1. 
This result suggests the intervention of Snail on PTEN 
expression, since high levels of Snail elicited by doxo 
cause PTEN downregulation whereas lower Snail levels 
are in accordance with a lower suppressive effect on 
PTEN expression. As expected, PTEN suppression was 
associated to an increase of Akt phosphorylation in doxo 
treated cells. Conversely, the milder PTEN downregulation 
was correlated to a reduction of Akt phosphorylation in 
doxo treated cells either exposed to ABT-888 or depleted 
of PARP-1. Therefore, we suggest that PARP-1, by 
regulating at transcriptional level the expression of the 
oncoprotein Snail, controls Akt phosphorylation through 
targeting PTEN expression.
Since we have shown that Snail contributes to activate 
survival pathways, its reduction, by offsetting these pathways, 
should result in higher cytotoxicity to the doxo treatment. 
Effectively, Snail deficiency of MDA-MB-231 cells 
showed an increased sensitivity to doxo-induced apoptosis. 
Moreover, Snail deficiency opposed to PTEN suppression 
elicited by doxo treatment, supporting the inhibitory role of 
Snail on PTEN expression. This result recalls the enhanced 
apoptosis obtained following PARP inhibition/depletion and 
suggests that the downregulation of Snail level may represent 
the crucial event to reach apoptosis.
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In conclusion, PARP-1 works as a kind of switch 
modulating Snail expression and hence the response 
to doxo treatment, as depicted in the model shown in 
Figure 6. The low apoptotic rate observed in MDA-
MB-231 cells exposed to doxo is correlated to the high 
expression levels of Snail oncoprotein. PARP-1 activation, 
which coincides with its displacement from SNAI1 locus, 
is required for Snail induction. The increased apoptotic 
rate is related to a lower upregulation of Snail. PARP-
1 seats on the promoter and controls, through its basal 
activity, Snail transcription.
Moreover, we showed that the lower upregulation of 
Snail is a fundamental event to the occurrence of apoptosis 
because it causes the recovery of PTEN expression. 
Further studies are required to clarify this molecular 
mechanism in detail.
In summary, the data of this study indicate that the 
lowering of Snail levels in cancer cells may represent a 
new crucial mechanism by which PARP inhibitors act 
sensitizing to chemotherapeutic drugs. In considering the 
mechanism of action of PARP inhibitors, it is important 
to keep in mind not only their function on DNA damage 
[71], but also on the regulation of cancer-related genes 
expression. We believe that more knowledge on the 
effect of PARP inhibitors in specific cell lines will allow 
to improve the outcome of specific subgroups of breast 
cancer patients.
MATERIALS AND METHODS
Cell cultures and treatments
Breast cancer cell lines MDA-MB-231, MDA-
MB-468, MDA-MB-157, MCF-7 (ATCC) were 
maintained in high glucose DMEM (Gibco, BRL) 
supplemented with 10% FBS (Gibco, BRL). All culture 
solutions were supplemented with 2 mM L-glutamine 
(Sigma-Aldrich) and 50 units/ml Penicillin-Streptomycin 
(Sigma-Aldrich). Treatments of cells were performed 
preparing mediums containing doxorubicin (Sigma-
Aldrich) at a final concentration of 1 μM and ABT-888 
(Veliparib) (Enzo Life Sciences) at a final concentration 
of 0.5 μM.
Colony forming assay
To evaluate cell colony-forming ability, 
exponentially growing MDA-MB-231 cells were treated 
with doxo 0.5 μM or ABT-888 0.5 μM alone or in 
combination for 2 hours. At the end of treatment, aliquots 
of cell suspension from each sample were seeded into 
60-mm Petri dishes with complete medium and incubated 
for three weeks. Colonies were stained with 2% methylene 
blue in 95% ethanol and counted. Percentage of colonies 
arising from surviving treated cells was calculated relative 
to colonies arising from untreated control cells.
Analysis of apoptosis by Annexin V staining
Induction of apoptosis was assessed by measuring 
Annexin V binding to externalized phosphatidylserine, 
as previously described [72]. Briefly, cells were washed 
twice with PBS and resuspended in binding buffer 10 
mM Hepes/NaOH pH 7.4, 140 mM NaCl, 2.5 mM 
CaCl2 (Sigma Chemical Co.). FITC conjugated Annexin 
V (Roche Diagnostic Corp.) was added at a final 
concentration of 1 μg/ml. The mixture was incubated at 
room temperature for 15 min in the dark. Stained cells 
were analyzed by flow cytometry using a Accuri C6 flow 
cytometer (Becton Dickinson), while simultaneously 
assessing membrane integrity by propidium iodide (PI) 
(0.25 μg/ml) exclusion. Samples were analyzed using the 
CFlow Plus software.
Western blot analysis
Total cell lysates were prepared in RIPA buffer 
(50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS and 1 mM EDTA) 
added with sodium orthovanadate 3 mM, NaF 100 mM 
supplemented with protease inhibitors (Sigma-Aldrich). 
Lysates were kept on ice for 25 min and then centrifuged 
at 16000 g for 30 min at 4°C. Supernatants were collected 
and quantified by Bradford protein assay reagent (Biorad). 
25 μg of proteins were loaded and separated by SDS-
PAGE and electroblotted onto nitrocellulose membrane 
(HybondTM ECLTM GE Healthcare). Immunoblots probed 
with the specific antibodies were developed using ECL 
or ECL Plus chemiluminescence reaction. The following 
antibodies were used: Snail (L70G2) (Cell Signaling), 
PARP-1 (clone C2–10 able to detect the 89kDa cleaved 
fragment of PARP-1; Enzo Life Sciences), PARP-1 (clone 
F1–23; Enzo Life Sciences), PAR (clone 10HA; Trevigen), 
Actin (Sigma-Aldrich), Akt (Cell Signaling), Phospho-
Akt (Ser473) (Cell Signaling), PTEN (Cell Signaling), 
Phospho-Histone H2AX (Ser139) (Millipore).
Quantitative real-time PCR
RNA was extracted with the RNeasy micro 
kit (Qiagen), and treated with RNase-free DNase 
(Qiagen). The RNA concentration and purity 
(260/280 and 260/230 ratios) was analyzed using a 
ND-1000 Spectrophotometer (NanoDrop Technologies). 
Total RNA was subjected to retrotranscription 
using SuperScript VILO cDNA Synthesis Kit (Life 
Technologies, Invitrogen). Quantitative Real-
Time PCR reactions were performed with KAPATM 
SYBR® FAST qPCR Kits (KAPA BIOSYSTEMS). 
The sense oligonucleotide for SNAI1 was 
5′-CTCTAATCCAGAGTTTACCTTC-3′ and the 
antisense was 5′-GACAGAGTCCCAGATGAG-3′. 
The sense oligonucleotide for PTEN was 
5′-ATGACAGCCATCATCAAAGAG-3′ and the 
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antisense was 5′-GTGCCACTGGTCTATAATCCA-3′. 
Gene expression analysis was performed using the 
comparative cycle threshold method with GAPDH for 
normalization. The sense oligonucleotide for GAPDH 
was 5′-CCAGTGACGTTCCCGTTCAGC-3′ and the 
antisense was 5′-CCCATCACCATCTCCCAGGAG-3′.
Transfection of MDA-MB-231 cells
MDA-MB-231 were transfected with 
Lipofectamine 2000 reagent (Life Technologies, 
Invitrogen) adopting the manufacturer’s protocol. For 
silencing experiments, cells were transfected with 
siGENOME SMARTpool PARP-1 and siGENOME 
Non-Targeting siRNA (Thermo Scientific, Dharmacon) 
at a final concentration of 50 nM. To generate Snail-
deficient cells, MDA-MB-231 were transfected 
with shRNA containing specific oligonucleotide 
sequences against EGFP (22 nt) or human Snail (19 
nt: 5′-GATGCACATCCGAAGCCAC-3′) cloned into 
the pSuperior-Puro vector (Oligoengine). The selection 
was obtained with puromycin 1 μg/ml (Invitrogen) for 
2–4 weeks. Appropriate expression levels of Snail were 
confirmed by immunoblotting.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as previously described 
[73]. The antibodies used for immunoprecipitation were: 
normal rabbit IgG (Santa Cruz), polyclonal antibody 
for PARP-1 (Enzo Lifescience), H3Ac (Millipore), 
H3K4me3 (Millipore) and H3K27me3 (Millipore). The 
sense oligonucleotide used to amplify the promoter 
region was 5′-AACCCCGCCTCGGAGGAGT-3′ 
and the antisense oligonucleotide was 
5′-CCAATCGGAGGCTCGTCT-3′. Real-Time PCR 
assays were carried out to amplify the enhancer region 
as already described [62]. The sense oligonucleotide 
used was FW 5′-GAGCAGCCCTTAATGACTTG-3′ 
and the antisense oligonucleotide was 
5′-CCCAACTCCCTAACTTCCC-3′. The sense 
oligonucleotide used to amplify the promoter region 
of ITPR1 was 5′-ACTGAGGTCGCGGTTTGTAT-3′ 
and the antisense oligonucleotide was 
5′-AAGGAGCCGTGTTGTGACTT-3′ [63].
Luciferase assay
For the luciferase assays, cells were transfected 
with Lipofectamine 2000 (Life Technologies, Invitrogen) 
FIGURE 6: Model of Snail transcriptional regulation by PARP-1 and effect of the differential Snail expression on 
apoptosis in MDA-MB-231 cells. The presence or absence of PARP-1 on the SNAI1 promoter/enhancer, which depends on the rate 
of PARP activity, affects the activity of SNAI1 promoter (see Discussion). After the doxorubicin treatment (left side), PARP activity 
increases and PARP-1 detaches from DNA probably bringing away repressive factors (gray circle) from the promoter while other positive 
transcription factors (blue circles) may bind it. This event causes a strong increase in Snail transcription (green circles) and the consequent 
repression of its target gene PTEN which results in resistance to apoptosis. After the treatment with doxo/ABT-888 (right side), PARP 
activity decreases and PARP-1 can bind the SNAI1 promoter/enhancer possibly causing the release of positive transcription factors from the 
promoter (light blue circles). The Snail transcription is lower, leading to a less efficacious repression of Snail on PTEN transcription and to 
a significant recovery of the apoptotic process.
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according to the manufacturer’s instructions. Cells were 
seeded in 12-well culture plates at a concentration of 2 x 
105 cells/well and incubated for 24 h prior to cotransfection 
involving luciferase reporter constructs. The vector 
containing luciferase under the control of human Snail 
promoter corresponding to sequences -598 to -578 (sense) 
and +92 to +72 (antisense) was obtained as indicated [61].
Statistical analysis
Statistical tests were performed using GraphPad 
Prism 6.0 and the number of replicates (n) performed are 
reported in figure legends. Data were considered to be 
statistically significant if *P < 0.05.
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